Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.
Also called NCT02513303
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 269 participants
- Sponsor
- Vascular Therapies, Inc.
- Registry
-
NCT02513303
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02513303. Randomized; triple masking; primary purpose prevention. Start 2015-11 (registry gives no type); primary completion 2021-06 (actual). Results posted on 2025-10-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
- Acronym
- ACCESS
- Condition
- Complication of Renal Dialysis
- Condition
- End Stage Renal Disease
- Condition
- End Stage Kidney Disease
- Condition
- ESRD
- Condition
- Chronic Kidney Failure
- Condition
- Complication of Hemodialysis
- Condition
- Vascular Access Complication
- Condition
- Arteriovenous Fistula
- Intervention (Drug)
- Sirolimus
- Intervention (Procedure)
- AV Fistula Surgery
- Intervention (Device)
- Sirolimus-eluting Collagen Implant (SeCI)
- Lead sponsor
- Vascular Therapies, Inc.
Record details
- Record id
cardio:ct-nct02513303- Content hash
748edbe67b094d2ab4b6ff1af8eb246c83f5c4ba1e8ad8959230e7e96332de1a